Summary
42 / 100 · Bulios Score
What speaks for it
- Revenue grew by 24% a year over the last 3 years.
- It has no debt and holds $39.2M in cash.
What to watch
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 0.1 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4,533.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 25% a year over 5 years. Over the last 3 years it grew by 24% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 58 USD
- Research and development 3.5 USD
- Sales and administration 39 USD
- Taxes and other -1.4 USD
- Net profit 0.1 USD
Net profit, industry median (Medical - Care Facilities) 6.8 USD
Out of every 100 USD of revenue, 0.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 8
- Sell 0
No analyst has published a price target.
20% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.